Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 151, Issue 1, 2016, Pages 37-44.e1

  Hachey, Krista J ^a   Hewes, Philip D ^a   Porter, Liam P ^a   Ridyard, Douglas G ^a   Rosenkranz, Pamela ^a   McAneny, David ^a   Fernando, Hiran C ^a   Litle, Virginia R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

embolism (venous); lung cancer; postoperative care

Indexed keywords

HEPARIN; OXYGEN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; CANCER PATIENT; CANCER SURGERY; CAPRINI RISK ASSESSMENT; CARDIOVASCULAR DISEASE ASSESSMENT; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DYSPNEA; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LENGTH OF STAY; LUNG CANCER; LUNG EMBOLISM; LUNG LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OXYGEN DESATURATION; POSTOPERATIVE THROMBOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THORAX PAIN; THROMBOSIS PREVENTION; ADVERSE EFFECTS; AGED; DECISION SUPPORT SYSTEM; DRUG ADMINISTRATION; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; LENGTH OF STAY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT SELECTION; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84959537939     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2015.08.039     Document Type: Conference Paper

References (28)

1. V.Q. Trinh, P.I. Karakiewicz, J. Sammon, M. Sun, S. Sukumar, M.K. Gervais, and et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care JAMA Surg 149 2014 43 49
2. R.P. Merkow, K.Y. Bilimoria, M.D. McCarter, M.E. Cohen, C.C. Barnett, M.V. Raval, and et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis Ann Surg 254 2011 131 137
3. D. Bergqvist, G. Agnelli, A.T. Cohen, A. Eldor, P.E. Nilsson, A. Le Moigne-Amrani, and et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N Engl J Med 346 2002 975 980
4. M.S. Rasmussen, L.N. Jorgensen, P. Wille-Jorgensen, J.D. Nielsen, A. Horn, A.C. Mohn, and et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized trial J Thromb Haemost 4 2006 2384 2390
5. R.D. Hull, G.F. Pineo, P.D. Stein, A.F. Mah, S.M. MacIsaac, O.E. Dahl, and et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review Ann Intern Med 135 2001 858 869
6. C.J. Pannucci, S.H. Bailey, G. Dreszer, C.F. Wachtman, J.W. Zumsteg, R.M. Jaber, and et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients J Am Coll Surg 212 2011 105 112
7. M.H. Huo, and J. Munt Extended thromboprophylaxis with low-molecular weight heparins after hospital discharge in high-risk surgical and medical patients: a review Clin Ther 31 2009 1121 1141
8. R.E. Nelson, S.D. Grosse, N.J. Waitzman, J. Lin, S.L. DuVall, O. Patterson, and et al. Using multiple sources of data for surveillance of postoperative venous thromboembolism among surgical patients treated in Department of Veterans Affairs hospitals, 2005-2010 Thromb Res 135 2015 636 642
9. M.J. Borkgren-Okonek, R.W. Hart, J.E. Pantano, P.C. Rantis, P.J. Guske, J.M. Kane, and et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity Surg Obes Relat Dis 4 2008 625 631
10. V. Bahl, H.M. Hu, P.K. Henke, T.W. Wakefield, D.A. Campbell, and J.A. Caprini A validation study of a retrospective venous thromboembolism risk scoring method Ann Surg 251 2010 244 350
11. M.R. Cassidy, P. Rosenkranz, and D. McAneny Reducing postoperative venous thromboembolism complications with a standardized risk-stratified prophylaxis protocol and mobilization program J Am Coll Surg 218 2014 1095 1104
12. W. Stroud, J.M. Whitworth, M. Miklic, K.E. Schneider, M.A. Finan, J. Scalici, and et al. Validation of a venous thromboembolism risk assessment model in gynecologic oncology Gynecol Oncol 134 2014 160 163
13. B.B. Yarlagadda, C.D. Brook, D.J. Stein, and S. Jalisi Venous thromboembolism in otolaryngology surgical inpatients receiving prophylaxis Head Neck 36 2014 1087 1093
14. M.K. Gould, D.A. Garcia, S.M. Wren, P.J. Karanicolas, J.I. Arcelus, J.A. Heit, and et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e227S e277S
15. A.C. Spyropoulos, and J. Lin Direct medical cost of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations J Manag Care Pharm 13 2007 475 486
16. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, E.P. Balaban, and et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 31 2013 2189 2204
17. M. Mandala, A. Falanga, and F. Roila ESMO Guidelines Working Group. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management Ann Oncol 21 Suppl 5 2010 v274 v276
18. R.R. De Martino, P.P. Goodney, E.L. Spangler, J.B. Wallaert, M.A. Corriere, E.M. Rzucidlo, and et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations J Vasc Surg 55 2012 1035 1041
19. M.H. Eslami, D. Rybin, G. Doros, and A. Farber Care of patients undergoing vascular surgery at safety net public hospitals is associated with higher cost but similar mortality to nonsafety net hospitals J Vasc Surg 60 2014 1627 1634
20. G.C. Connolly, L. Menapace, S. Safadjou, C.W. Francis, and A.A. Khorana Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients Clin Lung Cancer 14 2013 713 718
21. F.B. Rogers, M.D. Chipolle, G. Velmahos, G. Rozycki, and F.A. Luchette Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group J Trauma 53 2002 142 164
22. P.S. Wells, D.R. Anderson, J. Bormanis, F. Guy, M. Mitchell, L. Gray, and et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management Lancet 350 1997 1795 1798
23. M.T. Rondina, M. Wheeler, G.M. Rodgers, L. Draper, and R.C. Pendleton Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients Thromb Res 125 2010 220 223
24. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. [news release] 2012 US Food and Drug Administration Silver Spring, MD Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm
25. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, A.K. Kakkar, and et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
26. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, J. Muntz, and et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial Lancet 372 2008 31 39
27. B. Levitan, Z. Yuan, A.G. Turpie, R.J. Friendman, M. Homering, J.A. Berlin, and et al. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty Vasc Health and Risk Manag 10 2014 157 167
28. A. Duran, N. Sengupta, A. Diamantopoulos, F. Forster, L. Kwong, and M. Lees Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Pharmacoeconomics 30 2012 87 101